These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 14726731)

  • 1. Adolescent OxyContin Abuse.
    Katz DA; Hays LR
    J Am Acad Child Adolesc Psychiatry; 2004 Feb; 43(2):231-4. PubMed ID: 14726731
    [No Abstract]   [Full Text] [Related]  

  • 2. Oxycodone involvement in drug abuse deaths. II. Evidence for toxic multiple drug-drug interactions.
    Cone EJ; Fant RV; Rohay JM; Caplan YH; Ballina M; Reder RF; Haddox JD
    J Anal Toxicol; 2004; 28(4):217-25. PubMed ID: 15189671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxycodone involvement in drug abuse deaths. II. Evidence for toxic multiple drug-drug interactions.
    Cone EJ; Fant RV; Rohay JM; Caplan YH; Ballina M; Reder RF; Haddox JD
    J Anal Toxicol; 2004 Oct; 28(7):616-24. PubMed ID: 15516322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of abuse-deterrent OxyContin on prescription opioid utilization.
    Hwang CS; Chang HY; Alexander GC
    Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):197-204. PubMed ID: 25393216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What have we learned from OxyContin?
    Lipman AG
    J Pain Palliat Care Pharmacother; 2003; 17(1):1-4. PubMed ID: 14640335
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
    Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M
    Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder.
    Cassidy TA; Thorley E; Black RA; DeVeaugh-Geiss A; Butler SF; Coplan P
    J Opioid Manag; 2017; 13(6):425-440. PubMed ID: 29308589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004.
    Cicero TJ; Inciardi JA; Muñoz A
    J Pain; 2005 Oct; 6(10):662-72. PubMed ID: 16202959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An exploratory study of OxyContin use among individuals with substance use disorders.
    Levy MS
    J Psychoactive Drugs; 2007 Sep; 39(3):271-6. PubMed ID: 18159780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.
    Gudin J; Levy-Cooperman N; Kopecky EA; Fleming AB
    Pain Med; 2015 Nov; 16(11):2142-51. PubMed ID: 26108255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-medical use of OxyContin Tablets in the United States.
    Sees KL; Di Marino ME; Ruediger NK; Sweeney CT; Shiffman S
    J Pain Palliat Care Pharmacother; 2005; 19(2):13-23. PubMed ID: 16061457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OxyContin abuse.
    Suffett WL
    J Ky Med Assoc; 2001 Feb; 99(2):72. PubMed ID: 11441585
    [No Abstract]   [Full Text] [Related]  

  • 13. Oxycodone involvement in drug abuse deaths: a DAWN-based classification scheme applied to an oxycodone postmortem database containing over 1000 cases.
    Cone EJ; Fant RV; Rohay JM; Caplan YH; Ballina M; Reder RF; Spyker D; Haddox JD
    J Anal Toxicol; 2003 Mar; 27(2):57-67; discussion 67. PubMed ID: 12669998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seeking drug treatment for OxyContin abuse: a chart review of consecutive admissions to a substance abuse treatment facility in Kentucky.
    Hays L; Kirsh KL; Passik SD
    J Natl Compr Canc Netw; 2003 Jul; 1(3):423-8. PubMed ID: 19761073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study.
    Degenhardt L; Bruno R; Ali R; Lintzeris N; Farrell M; Larance B
    Drug Alcohol Depend; 2015 Jun; 151():56-67. PubMed ID: 25910850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.
    Severtson SG; Ellis MS; Kurtz SP; Rosenblum A; Cicero TJ; Parrino MW; Gilbert MK; Buttram ME; Dasgupta N; BucherBartelson B; Green JL; Dart RC
    Drug Alcohol Depend; 2016 Nov; 168():219-229. PubMed ID: 27716575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent properties.
    Cheng HG; Coplan PM
    Postgrad Med; 2018 Aug; 130(6):568-574. PubMed ID: 29978755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OxyContin abuse: who are the users?
    Rawson RA; Maxwell J; Rutkowski B
    Am J Psychiatry; 2007 Nov; 164(11):1634-6. PubMed ID: 17974924
    [No Abstract]   [Full Text] [Related]  

  • 19. Responding rationally to recent report of abuse/diversion of Oxycontin.
    Passik SD
    J Pain Symptom Manage; 2001 May; 21(5):359. PubMed ID: 11398786
    [No Abstract]   [Full Text] [Related]  

  • 20. OxyContin abuse and diversion and efforts to address the problem: highlights of a government report.
    Government Accounting Office
    J Pain Palliat Care Pharmacother; 2004; 18(3):109-13. PubMed ID: 15364638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.